Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 11, 2016, Pages 1619-1628

  Goossens, Nicolas ^a,b   Hoshida, Yujin ^b   Song, Won Min ^c   Jung, Minoa ^a   Morel, Philippe ^a   Nakagawa, Shigeki ^b   Zhang, Bin ^c   Frossard, Jean Louis ^a   Spahr, Laurent ^a   Friedman, Scott L ^b   Negro, Francesco ^a   Rubbia Brandt, Laura ^a   Giostra, Emiliano ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Fatty Liver Disease; NHANES III; Postoperative Complication; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTRIC BYPASS SURGERY; GENE EXPRESSION PROFILING; HEALTH SURVEY; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY III; NONALCOHOLIC FATTY LIVER; OBESITY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURGICAL MORTALITY; BARIATRIC SURGERY; BIOPSY; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; ECHOGRAPHY; LIVER; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS; SWITZERLAND;

ADULT; ALANINE TRANSAMINASE; BARIATRIC SURGERY; BIOPSY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SWITZERLAND; ULTRASONOGRAPHY;

EID: 84975156689     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.10.010     Document Type: Article

References (34)

1. 1 Finkelstein, E.A., Trogdon, J.G., Cohen, J.W., et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff 28 (2009), w822–w831.
2. 2 Ogden, C.L., Carroll, M.D., Kit, B.K., et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311 (2014), 806–814.
3. 3 Ng, M., Fleming, T., Robinson, M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study. Lancet 384 (2013), 766–781.
4. 4 Browning, J.D., Szczepaniak, L.S., Dobbins, R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
5. 5 Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
6. 6 Machado, M., Marques-Vidal, P., Cortez-Pinto, H., Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45 (2006), 600–606.
7. 7 Puzziferri, N., Roshek, T.B. 3rd, Mayo, H.G., et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA 312 (2014), 934–942.
8. 8 Adams, T.D., Gress, R.E., Smith, S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 357 (2007), 753–761.
9. 9 Sjöström, L., Narbro, K., Sjöström, C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007), 741–752.
10. 10 Maciejewski, M.L., Livingston, E.H., Smith, V.A., et al. Survival among high-risk patients after bariatric surgery. JAMA 305 (2011), 2419–2426.
11. 11 Flum, D.R., Belle, S.H., King, W.C., et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 361 (2009), 445–454.
12. 12 Thomas, H., Agrawal, S., Systematic review of obesity surgery mortality risk score: preoperative risk stratification in bariatric surgery. Obes Surg 22 (2012), 1135–1140.
13. 13 Livingston, E.H., Huerta, S., Arthur, D., et al. Male gender is a predictor of morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery. Ann Surg 236 (2002), 576–582.
14. 14 Arterburn, D., Livingston, E.H., Schifftner, T., et al. Predictors of long-term mortality after bariatric surgery performed in veterans affairs medical centers. Arch Surg 144 (2009), 914–920.
15. 15 Chassot, G., Huber, O., Koutny-Fong, P., et al. [Surgical treatment of obesity in 2006]. Rev Med Suisse 2 (2006), 1568–1571.
16. 16 Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
17. 17 Brunt, E.M., Kleiner, D.E., Wilson, L.A., et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53 (2011), 810–820.
18. 18 Centers for Disease Control Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey III, 1988-1994. 1998, U.S. Department of Health and Human Services, CDC, Hyattsville, MD.
19. 19 King, L.Y., Canasto-Chibuque, C., Johnson, K.B., et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 64 (2014), 1296–1302.
20. 20 Hoshida, Y., Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PloS One, 5, 2010, e15543.
21. 21 Song, W.-M., Di Matteo, T., Aste, T., Building complex networks with platonic solids. Physical Review E, 85, 2012, 046115.
22. 22 Song, W.-M., Di Matteo, T., Aste, T., Nested hierarchies in planar graphs. Discrete Appl Math 159 (2011), 2135–2146.
23. 23 Moylan, C.A., Pang, H., Dellinger, A., et al. Hepatic gene expression profiles differentiate pre-symptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 59 (2013), 471–482.
24. 24 Fuchs, B.C., Hoshida, Y., Fujii, T., et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 59 (2014), 1577–1590.
25. 25 Drews, F., Knobel, S., Moser, M., et al. Disruption of the latent transforming growth factor-beta binding protein-1 gene causes alteration in facial structure and influences TGF-beta bioavailability. Biochim Biophys Acta 1783 (2008), 34–48.
26. 26 Zhang, D., Goossens, N., Guo, J., et al. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2015 (Epub ahead of print).
27. 27 Mathurin, P., Hollebecque, A., Arnalsteen, L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137 (2009), 532–540.
28. 28 Lassailly, G., Caiazzo, R., Buob, D., et al. Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149 (2015), 379–388.
29. 29 Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.e10.
30. 30 Ekstedt, M., Hagstrom, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
31. 31 Henao-Mejia, J., Elinav, E., Jin, C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
32. 32 Lazo, M., Hernaez, R., Bonekamp, S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ, 2011, 343.
33. 33 Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
34. 34 Nguyen, N.T., Masoomi, H., Magno, C.P., et al. Trends in use of bariatric surgery, 2003−2008. J Am Coll Surg 213 (2011), 261–266.